Table 4.

CYP1A1, CYP1A2, CYP1B1, COMT, GSTM1, and GSTT1 genotypes and endometrial cancer risk

GenotypeCases (n = 371), n (%)Controls (n = 420), n (%)OR, age adjusted (95% CI)P for HWE in controls
CYP1A1 m1
    TT317 (85)331 (79)1.00 (Reference)0.12
    ≥1 C54 (15)89 (21)0.64 (0.44-0.93)
        TC53 (14)80 (19)0.69 (0.47-1.02)
        CC1 (<1)9 (2)0.12 (0.02-0.95)
CYP1A1 m2
    Ile/Ile354 (95)386 (92)1.00 (Reference)0.74
    ≥1 Val17 (5)34 (8)0.54 (0.30-0.99)
        Ile/Val17 (5)33 (8)
        Val/Val0 (0)1 (<1)
CYP1A1 m4
    Thr/Thr337 (91)384 (91)1.00 (Reference)0.36
    ≥1 Asn34 (9)36 (9)1.10 (0.67-1.80)
        Thr/Asn33 (9)36 (9)
        Asn/Asn1 (<1)0 (0)
CYP1A2
    AA197 (53)221 (53)1.00 (Reference)0.63
    ≥1 C174 (47)199 (47)0.98 (0.74-1.30)
        AC142 (38)170 (40)0.93 (0.69-1.25)
        CC32 (9)29 (7)1.24 (0.72-2.12)
CYP1B1
    Leu/Leu115 (31)145 (35)1.00 (Reference)0.27
    ≥1 Val256 (69)275 (65)1.18 (0.87-1.59)
        Val/Leu170 (46)194 (46)1.11 (0.81-1.53)
        Val/Val86 (23)81 (19)1.34 (0.90-1.98)
COMT
    Val/Val97 (26)90 (21)1.00 (Reference)0.87
    ≥1 Met274 (73)330 (78)0.77 (0.55-1.07)
        Val/Met174 (47)207 (49)0.78 (0.55-1.10)
        Met/Met100 (27)123 (29)0.75 (0.51-1.11)
GSTM1
    Present190 (51)200 (48)1.00 (Reference)NA*
    Null181 (49)220 (52)0.87 (0.65-1.15)
GSTT1
    Present293 (79)359 (85)1.00 (Reference)NA*
    Null78 (21)61 (15)1.55 (1.07-2.24)
  • * HWE could not be tested because the assay detects the presence or absence of the allele, not the number of copies.